In responders (n = 59) and in non-responders (n = 9), ZNF217 expression was associated with response to neoadjuvant ET, since ZNF217 mRNA expression levels tended to be significantly higher (P = 0.05) in the initial breast tumor in patients who did not respond to neoadjuvant ET (median = 5.98) than those who did (median = 3.01) (Figure 1A). The gene discussed is ZNF217; the disease is breast neoplasm.